{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-03T12:40:51.855891+00:00","company":{"ticker":"DLB","cik":1308547,"company_name":"Dolby Laboratories, Inc."},"pagination":{"limit":100,"returned":3,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"3166bd361922c0184f8cd45eca019953cd56a43a","cik":1308547,"ticker":"DLB","company_name":"Dolby Laboratories, Inc.","filed_at":"2026-04-30T23:59:59+00:00","payload":{"eps_text":"$0.99 per diluted share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$95 million or $0.99 per diluted share","period_text":"the second quarter of fiscal 2026","report_date":"2026-04-30","result_type":"reported_results","revenue_text":"$396 million"},"claim":"Dolby Laboratories, Inc. reported the second quarter of fiscal 2026 results: revenue $396 million, net income $95 million or $0.99 per diluted share, EPS $0.99 per diluted share.","evidence_excerpt":"Total revenue was $396 million, compared to $370 million for the second quarter of fiscal 2025. • GAAP net income was $95 million or $0.99 per diluted share, compared to GAAP net income of $92 million or $0.94 per diluted share for the second quarter of fiscal 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-26-197338","anchor_url":"https://secwatch.observer/filing/0001193125-26-197338#claim-3166bd361922c0184f8cd45eca019953cd56a43a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1308547/000119312526197338/0001193125-26-197338-index.htm"},{"fact_type":"earnings_release","fact_key":"637dfc3bce8f69a3d2051b872dec8bc6396132c8","cik":1308547,"ticker":"DLB","company_name":"Dolby Laboratories, Inc.","filed_at":"2024-05-02T23:59:59+00:00","payload":{"eps_text":"$0.21 to $0.36 on a GAAP basis and from $0.51 to $0.66 on a non-GAAP basis for Q3; $2.30 to $2.45 on a GAAP basis and fr","guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"third quarter of fiscal 2024 and full year of fiscal 2024","report_date":"2024-05-02","result_type":"guidance_update","revenue_text":null},"claim":"Dolby Laboratories, Inc. reported third quarter of fiscal 2024 and full year of fiscal 2024 results: EPS $0.21 to $0.36 on a GAAP basis and from $0.51 to $0.66 on a non-GAAP basis for Q3; $2.30 to $2.45 on a GAAP basis and fr. Guidance reaffirmed.","evidence_excerpt":"Total revenue is estimated to range from $270 million to $300 million.","confidence":0.7,"filing_url":"https://secwatch.observer/filing/0001193125-24-129380","anchor_url":"https://secwatch.observer/filing/0001193125-24-129380#claim-637dfc3bce8f69a3d2051b872dec8bc6396132c8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1308547/000119312524129380/0001193125-24-129380-index.htm"},{"fact_type":"earnings_release","fact_key":"8d5100516b6ecf05a218a135a88eda33aeef5136","cik":1308547,"ticker":"DLB","company_name":"Dolby Laboratories, Inc.","filed_at":"2024-05-02T23:59:59+00:00","payload":{"eps_text":"$1.01 per diluted share","guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":"$97.8 million","period_text":"second quarter of fiscal 2024","report_date":"2024-05-02","result_type":"reported_results","revenue_text":"$364.5 million"},"claim":"Dolby Laboratories, Inc. reported second quarter of fiscal 2024 results: revenue $364.5 million, net income $97.8 million, EPS $1.01 per diluted share. Guidance reaffirmed.","evidence_excerpt":"sports, music and more, driving more consumer device adoption and bringing Dolby to more people worldwide.” Second Quarter Fiscal 2024 Financial Highlights • Total revenue was $364.5 million, compared to $375.9 million for the second quarter of fiscal 2023. • GAAP net income was $97.8 million, or $1.01 per diluted share, compared to GAAP net income of $95.7 million,","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-24-129380","anchor_url":"https://secwatch.observer/filing/0001193125-24-129380#claim-8d5100516b6ecf05a218a135a88eda33aeef5136","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1308547/000119312524129380/0001193125-24-129380-index.htm"}]}